Contract analysis

1. Respondent Whitmore Aerospace LLC ("WAL" or "Respondent") respectfully submits this Statement of Defense and Counterclaim to the Tribunal in response to the Statement of Claim filed by Kestrel Dynamics GmbH ("Kestrel" or "Claimant") on April 28, 2023, in accordance with the procedural calendar established by the Tribunal in Procedural Order No. 1 dated February 14, 2023.

2. WAL is a privately held Delaware limited liability company headquartered at 4200 Wilson Boulevard, Suite 1100, Arlington, Virginia 22203. WAL is engaged in the business of aerospace and defense manufacturing, specializing in propulsion systems and structural airframe components for both military and commercial aviation platforms. For the fiscal year ending December 31, 2022, WAL reported annual revenue of approxim

3. Kestrel is a Gesellschaft mit beschränkter Haftung organized and existing under the laws of the Federal Republic of Germany, registered in the German Trade Register under No. HRB 745621 at the Amtsgericht Stuttgart, with its principal offices at Industriestraße 88, 70565 Stuttgart, Germany. Kestrel specializes in precision-machined titanium and nickel-alloy turbine housings and high-temperature exhaust assemblies

4. Kestrel commenced this arbitration by filing its Request for Arbitration with the International Chamber of Commerce on November 7, 2022, alleging that WAL committed material breach of the Master Supply Agreement for Titanium Alloy Turbine Housings dated June 15, 2018 (the "MSA," internally referenced as WAL-KDG-MSA-2018-0615). In its Statement of Claim, Kestrel seeks damages in the aggregate amount of approximatel

5. WAL denies Kestrel's allegations in their entirety. The record in this matter will demonstrate that WAL's termination of the MSA on October 3, 2022 was proper and fully justified under Section 14.2(b) of the MSA, which grants either party the right to terminate upon the occurrence of a "Persistent Quality Failure" as defined in Section 8.4. Far from committing material breach, WAL acted in strict accordance with i

6. In addition to defending against Kestrel's unfounded claims, WAL asserts a counterclaim against Kestrel in the amount of €5.17 million. This sum represents the direct cost premium that WAL incurred in procuring replacement titanium alloy turbine housings from Valkyr Precision Components Inc. ("Valkyr") following Kestrel's Persistent Quality Failure. WAL was compelled to source 1,680 replacement units from Valkyr a

7. This Statement of Defense and Counterclaim is organized as follows: Section II sets forth the relevant procedural history; Section III describes the key provisions of the MSA; Section IV presents WAL's statement of the material facts; Section V responds to each of Kestrel's principal allegations; Section VI addresses and rebuts each category of Kestrel's claimed damages; Section VII sets forth WAL's counterclaim;

II. PROCEDURAL HISTORY A. Execution and Amendments to the MSA

8. On June 15, 2018, WAL, as Buyer, and Kestrel, as Seller, executed the Master Supply Agreement for Titanium Alloy Turbine Housings (internally referenced as WAL-KDG-MSA-2018-0615) (the "MSA"). The MSA is the governing agreement between the parties that establishes the terms and conditions for Kestrel's manufacture and delivery of Ti-6Al-4V ELI titanium alloy turbine housings to WAL. A true and correct copy of the M

9. The MSA was entered into for an initial term of five years, commencing on June 15, 2018 and expiring on June 14, 2023, with two optional one-year renewal periods exercisable solely at WAL's discretion (Section 3.1 of the MSA). The MSA was the product of extensive arm's-length negotiations between two sophisticated commercial entities, each represented by experienced counsel and each possessing substantial expertis

10. The MSA was amended on two occasions during its term: (a) Amendment No. 1, dated February 10, 2020. Amendment No. 1 expanded the scope of the MSA to include Products manufactured to WAL engineering specification WAL-SPEC-TH-410, a high-temperature variant of the turbine housing designed for next-generation propulsion applications. Amendment No. 1 also increased the maximum annual volume from 3,600 to 4,000 units

11. It bears emphasis that Amendment No. 2 was a concession made by WAL in Kestrel's favor, extending the cure period by 50% (from 30 to 45 days). Despite this accommodation, Kestrel was still unable to cure a substantial number of rejected lots within the extended timeframe, as discussed in detail below. B. The Dispute and Termination

12. Beginning in March 2022, WAL's incoming quality-control inspections began identifying elevated porosity levels in Products delivered by Kestrel. Between March 7, 2022 (the delivery date of Lot KDG-2022-0307) and September 19, 2022 (the delivery date of Lot KDG-2022-0919), WAL rejected a total of 14 lots of Products, comprising 1,680 individual units, for non-conformance with the contractual porosity specification

13. For each rejected lot, WAL provided Kestrel with timely written notice of rejection specifying the nature of the non-conformance and affording Kestrel the opportunity to cure within the 45-calendar-day period mandated by Section 8.4, as amended by Amendment No. 2. Of the 14 rejected lots, Kestrel successfully cured 7 by delivering replacement or reworked units within the cure period. However, for the remaining 7

14. Under Section 8.4 of the MSA, three or more uncured rejections within any rolling 12-month period constitute a "Persistent Quality Failure." With 7 uncured rejections — more than double the contractual threshold — the occurrence of a Persistent Quality Failure was beyond dispute. Accordingly, on October 3, 2022, WAL issued its Notice of Termination for Cause under Section 14.2(b) of the MSA, identifying the 7 unc

15. The procedural history of this arbitration is as follows: (a) On November 7, 2022, Kestrel filed its Request for Arbitration with the International Chamber of Commerce, International Court of Arbitration, pursuant to the arbitration clause contained in Section 22.3 of the MSA. (b) On December 12, 2022, WAL filed its Answer to the Request for Arbitration and Counterclaim with the ICC, denying Kestrel's allegations

16. This Statement of Defense and Counterclaim is filed in accordance with the procedural calendar established in Procedural Order No. 1. WAL reserves all rights to submit further evidence and argument in accordance with the Tribunal's orders and the applicable ICC Rules of Arbitration.

III. THE MASTER SUPPLY AGREEMENT

17. This Section summarizes the key provisions of the MSA relevant to the issues in dispute. The full text of the MSA is submitted as Exhibit R-1, and the full texts of Amendment No. 1 and Amendment No. 2 are submitted as Exhibits R-2 and R-3, respectively. A. Scope of the MSA

18. Under the MSA, Kestrel agreed to manufacture and deliver Ti-6Al-4V ELI (Extra Low Interstitial) titanium alloy turbine housings (the "Products") in accordance with WAL's engineering specifications WAL-SPEC-TH-401 through WAL-SPEC-TH-409 (Section 2.1). Following the execution of Amendment No. 1, the scope of the MSA was expanded to include Products manufactured to WAL engineering specification WAL-SPEC-TH-410, a h

19. The Products are mission-critical components used in WAL's propulsion systems and structural airframe assemblies. The quality and dimensional integrity of the Products are essential to the safety and performance of the end-use platforms. For this reason, the MSA contained rigorous quality specifications and testing protocols, which Kestrel expressly agreed to satisfy.

20. Delivery of the Products was to be made DDP (Delivered Duty Paid) to WAL's manufacturing facility located at 8500 Coppermine Road, Manassas, Virginia 20110, in accordance with Incoterms 2020 (Section 6.1). Under the DDP delivery term, Kestrel bore all costs and risks associated with transporting the Products to WAL's facility, including customs duties, import clearances, and insurance. B. Volume and Pricing

21. The MSA established both minimum and maximum annual volume commitments: (a) Minimum Annual Volume Commitment: WAL committed to order a minimum of 2,400 units of Products per contract year (Section 4.1). This minimum volume commitment reflected WAL's baseline production requirements and provided Kestrel with a guaranteed minimum revenue floor. (b) Maximum Annual Volume: The maximum annual volume was initially set

22. Pricing for the Products was established on a per-unit basis, with a 2.5% annual escalator compounded annually in accordance with Section 5.2. The per-unit prices for each contract year were as follows:

23. At the minimum annual volume of 2,400 units, the aggregate contract value over the five-year initial term was approximately €61.2 million. The pricing structure reflected the arm's-length negotiation between the parties and accounted for anticipated increases in raw material costs, labor costs, and other inputs. C. Quality Requirements

24. The MSA imposed stringent quality requirements on Kestrel, reflecting the safety-critical nature of the Products and the regulatory environment in which WAL operates. The principal quality requirements include the following: (a) AS9100 Rev D Certification. Kestrel was required to maintain AS9100 Rev D certification — the internationally recognized quality management system standard for the aviation, space, and de

25. The porosity specification of ≤0.25% reflects an industry-standard requirement for Ti-6Al-4V ELI titanium alloy components used in safety-critical aerospace applications. Porosity — the presence of voids or gas pockets within the metal matrix — directly affects the structural integrity, fatigue life, and fracture resistance of titanium alloy components. Elevated porosity levels can lead to premature fatigue failu

26. Section 8.4 of the MSA establishes the framework for rejection of non-conforming lots and the cure process: (a) If WAL rejects a lot for non-conformance with the applicable specifications, WAL shall provide written notice to Kestrel specifying the nature of the non-conformance. (b) Upon receipt of a rejection notice, Kestrel shall have 45 calendar days (as amended by Amendment No. 2; originally 30 calendar days)

27. The Persistent Quality Failure provision serves a critical function in the contractual framework. It provides a clear, objective, and measurable threshold beyond which a pattern of quality non-conformance is deemed sufficiently serious to warrant termination. The threshold of three uncured rejections in a rolling 12-month period was negotiated between the parties as a reasonable standard that would protect WAL ag

28. Section 8.7 of the MSA establishes the exclusive remedies available to WAL in the event of quality failures and contains a mutual waiver of consequential damages. Specifically: (a) WAL's remedies for quality failures are limited to (i) replacement of non-conforming Products at Kestrel's cost, (ii) credit against future orders, or (iii) termination of the MSA upon the occurrence of a Persistent Quality Failure in

29. The consequential damages waiver was a material term of the MSA, negotiated at arm's length between two sophisticated commercial parties with extensive experience in aerospace contracting. As will be demonstrated below, this waiver bars the majority of Kestrel's claimed damages. F. Termination for Cause (§ 14.2)

30. Section 14.2 of the MSA provides two grounds for termination for cause: (a) Section 14.2(a) — Material Breach. Either party may terminate the MSA upon a material breach by the other party that remains uncured for 60 calendar days following written notice specifying the breach. (b) Section 14.2(b) — Persistent Quality Failure. Either party may terminate the MSA upon the occurrence of a Persistent Quality Failure,

31. WAL terminated the MSA under Section 14.2(b) on October 3, 2022, following the occurrence of a Persistent Quality Failure comprising seven uncured rejections within a single rolling 12-month period. WAL did not terminate under Section 14.2(a), and the analysis of whether a "material breach" occurred under general principles of contract law is accordingly irrelevant to the propriety of WAL's termination — the term

32. The MSA is governed by the laws of the State of New York, without regard to its conflict-of-laws principles (Section 22.1). All disputes arising out of or in connection with the MSA are to be resolved by arbitration administered by the International Chamber of Commerce under the ICC Rules of Arbitration (2021 edition), before a tribunal of three arbitrators, with the seat of arbitration in New York, New York (Sec

IV. STATEMENT OF FACTS A. Performance Under the MSA (2018–2021)

33. From the date of execution of the MSA on June 15, 2018 through early 2022, the contractual relationship between WAL and Kestrel proceeded without significant quality disputes. During this period, Kestrel manufactured and delivered Products to WAL in substantial conformity with the MSA's specifications, and WAL accepted the vast majority of deliveries following its standard incoming inspection process under WAL-QC

34. The key WAL personnel involved in the day-to-day management of the supply relationship with Kestrel were Gerald Huang, Vice President of Global Supply Chain Operations, who was responsible for procurement, vendor management, and commercial communications with Kestrel; and Dr. Ingrid Vollmer, Senior Vice President of Engineering and Manufacturing, who oversaw the quality-control inspection process and the applicat

35. The principal Kestrel personnel with whom WAL interacted were Friedrich Brenner, Managing Director (Geschäftsführer) of Kestrel, who held ultimate responsibility for Kestrel's business operations; Luisa Erdmann, Commercial Director, who served as the primary commercial contact and liaison with WAL; and Dr. Stefan Voss, Head of Quality Assurance, who was responsible for Kestrel's internal quality-control processes

36. During the first three-and-a-half years of the MSA's term, there were occasional isolated quality excursions — as is normal in any high-volume precision-manufacturing relationship — but these were addressed through the contractual cure mechanisms without escalation. Kestrel's track record during this period demonstrates that the ≤0.25% porosity specification was achievable and was in fact consistently achieved by

37. Beginning in March 2022, WAL's incoming inspection under WAL-QCP-100 began detecting elevated porosity levels in Products delivered by Kestrel. The first rejected lot was Lot KDG-2022-0307, delivered to WAL's Manassas facility on or about March 7, 2022. WAL's testing of Lot KDG-2022-0307 revealed porosity levels at multiple sample points within the lot that exceeded the contractual maximum of ≤0.25% as establishe

38. The rejection of Lot KDG-2022-0307 was followed by a cascading series of additional quality failures over the ensuing six months. Between March 7, 2022 and September 19, 2022, WAL rejected a total of 14 lots comprising 1,680 individual units for non-conformance with the contractual porosity specifications. The final rejected lot in this series was Lot KDG-2022-0919, delivered on or about September 19, 2022. The l

39. To confirm the accuracy and reliability of its incoming inspection results, WAL engaged Arclight Materials Science Inc. ("Arclight"), a nationally recognized independent metallurgical testing laboratory headquartered at 7900 Westpark Drive, Suite 200, McLean, Virginia 22102, to conduct independent testing of samples from the rejected lots. The independent testing was conducted under the supervision of Dr. Raymond

40. It is important to address the range of porosity measurements at this stage, as WAL anticipates that Kestrel will attempt to exploit the fact that some measurements within the rejected lots fell below 0.25%. As explained in further detail in Section V.B below, the porosity measurements represent results from multiple sample points within each lot. Under WAL-QCP-100, a lot is accepted or rejected on a lot-wide bas

41. For each of the 14 rejected lots, WAL followed the contractual rejection and cure process precisely as specified in Section 8.4 of the MSA, as amended by Amendment No. 2. Specifically: (a) Upon completing its incoming inspection and determining that a lot failed to meet the contractual specifications, WAL issued timely written notice of rejection to Kestrel. Each rejection notice identified the specific lot numbe

42. Of the 14 rejected lots, Kestrel successfully cured 7. For these 7 lots, Kestrel delivered replacement or reworked units within the 45-calendar-day cure period that conformed to the ≤0.25% porosity specification upon re-inspection by WAL. WAL accepted these cured lots and integrated the replacement units into its production processes.

43. For the remaining 7 lots, Kestrel failed to cure within the 45-calendar-day period. In some instances, Kestrel attempted cure but delivered replacement or reworked units that also failed inspection. In other instances, Kestrel failed to deliver any cure within the prescribed timeframe. In all 7 cases, the cure period expired without a successful cure, and the rejections were accordingly deemed "uncured" under Sec

44. The 7 uncured rejections occurred between March and September 2022 — a span of approximately seven months, well within a single rolling 12-month period. The contractual threshold for a Persistent Quality Failure under Section 8.4 is three uncured rejections within any rolling 12-month period. With 7 uncured rejections, WAL exceeded the threshold by more than double, leaving no reasonable dispute that a Persistent

45. Throughout the March–September 2022 period, WAL maintained regular correspondence with Kestrel regarding the quality failures and the status of cure efforts. Correspondence between Gerald Huang (WAL) and Luisa Erdmann (Kestrel) during this period reflects WAL's repeated notifications of the porosity non-conformances, requests for root-cause analysis, and expressions of concern regarding the escalating pattern of

46. Similarly, technical-level correspondence between Dr. Ingrid Vollmer (WAL) and Dr. Stefan Voss (Kestrel) during the same period reflects WAL's detailed communication of the inspection results, including specific porosity measurements, sample point locations, and applicable specification requirements. Dr. Vollmer repeatedly urged Dr. Voss to identify and address the root cause of the porosity exceedances and offer

47. Kestrel acknowledged receipt of the rejection notices and the associated correspondence. However, Kestrel failed to identify or remediate the root cause of the persistent porosity exceedances. Kestrel's responses, while timely in form, were substantively inadequate. Kestrel did not provide WAL with any credible root-cause analysis during the relevant period, did not demonstrate that it had implemented effective c

48. Of particular significance, Kestrel's own internal quality-assurance records — obtained by WAL through the document production process conducted pursuant to Procedural Order No. 2 — demonstrate that Kestrel's internal testing identified porosity levels above 0.25% in several of the rejected lots prior to shipment to WAL. These records, submitted as Exhibit R-15, reveal that Dr. Stefan Voss's quality-assurance tea

49. On October 3, 2022, following the expiration of the cure period for the seventh uncured lot rejection, WAL issued its Notice of Termination for Cause to Kestrel in accordance with Section 14.2(b) of the MSA. The notice was delivered in writing to Kestrel at its registered address and to its Commercial Director, Luisa Erdmann, by both overnight courier and electronic mail. A true and correct copy of the Notice of

50. The Notice of Termination for Cause identified the following: (a) The occurrence of a Persistent Quality Failure under Section 8.4, consisting of seven uncured rejections within a single rolling 12-month period, far exceeding the contractual threshold of three; (b) The specific lot numbers of the seven uncured rejected lots; (c) The nature of the non-conformance for each lot (porosity exceedance above the ≤0.25%

51. The termination was procedurally proper in all respects. WAL complied with the notice requirements of the MSA, identified the specific contractual basis for termination, and provided Kestrel with full transparency regarding the grounds for its decision. The termination was also substantively proper: the Persistent Quality Failure had unambiguously occurred, the contractual conditions for termination under Section

52. Following Kestrel's repeated quality failures and WAL's termination of the MSA, WAL was faced with an urgent need to secure an alternative source of specification-compliant Ti-6Al-4V ELI titanium alloy turbine housings. WAL's downstream manufacturing operations depend on a continuous supply of these safety-critical components, and any extended disruption in supply would have jeopardized WAL's ability to meet its

53. After conducting a competitive solicitation among qualified alternative suppliers, WAL engaged Valkyr Precision Components Inc. ("Valkyr"), a U.S.-based precision aerospace components manufacturer headquartered at 4401 East Irvington Road, Tucson, Arizona 85714, as its replacement supplier for titanium alloy turbine housings. Valkyr is an AS9100 Rev D-certified manufacturer with established capabilities in Ti-6Al

54. Three aspects of WAL's engagement of Valkyr warrant particular emphasis in the context of this arbitration: (a) Timing. The decision to engage Valkyr was made after, not before, Kestrel's Persistent Quality Failure and WAL's lawful termination of the MSA. WAL did not pre-arrange a replacement supplier as part of a premeditated scheme to terminate the MSA. To the contrary, WAL engaged Valkyr as an emergency mitiga

55. WAL sourced 1,680 replacement units from Valkyr at the premium price to replace the non-conforming Products that Kestrel had failed to deliver in specification-compliant form. The per-unit cost premium and the total cost of replacement form the basis of WAL's counterclaim, as set forth in Section VII below.

V. RESPONSE TO CLAIMANT'S ALLEGATIONS